Fig 2: Expression of LILRA3 and LILRA5 on CD34+ cells, CD3+ cells, CD8+ cells and CD11C+ HLA-DR+ cells. (A) Expression assessed using flow cytometry. (B) LILRA3 and LILRA5 expression on CD34+, CD3+, CD8+ and CD11C+ HLA-DR+ cells in patients with SAA and normal controls. LILRA, leukocyte immunoglobulin-like receptors A; R-SAA, remission-treated severe aplastic anemia; PLT, platelets; HB, hemoglobin; HLA, human leukocyte antigen; SSC, side scatter.

Fig 3: Verification of the mDC phenotype and expression of LILRA3. (A) Analysis of mDCs using flow cytometry (day 7) and microscopy (arrow indicates gradually maturing dendritic cells). (B) Relative expression of LILRA3 mRNA in mDCs determined using reverse transcription-quantitative PCR (left). LILRA3 in serum was measured using ELISA (middle). The relative expression of LILRA3 in mDCs determined using western blot analysis (right). LILRA, leukocyte immunoglobulin-like receptors A; mDCs, myeloid dendritic cells; HLA, human leukocyte antigen; R-SAA, remission-treated severe aplastic anemia.

Fig 4: (A) LILRA3 expression was closely associated with the clinical characteristics of patients with SAA. (B) Correlations of LILRA3 mRNA with cytokines TNF-a, IFN-?, IL-4 and IL-10 in patients with untreated severe aplastic anemia. LILRA, leukocyte immunoglobulin-like receptors A.